The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Ipilimumab Immunotherapy: CTLA-4 Checkpoint Inhibitor

T-cell priming, combination regimens and toxicity management

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Ipilimumab Immunotherapy: CTLA-4 Checkpoint Inhibitor?

Ipilimumab is an IgG1 fully human monoclonal antibody targeting CTLA-4 on activated T cells and regulatory T cells.

By blocking CTLA-4 it removes a key brake on T-cell priming, expanding the antigen-specific T-cell repertoire against tumors.

Standard dosing is 3 mg/kg every 3 weeks for four cycles in monotherapy melanoma; combination regimens use 1 mg/kg every 3 or 6 weeks.

Approved combinations include ipilimumab plus nivolumab for advanced melanoma, renal cell carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma and mesothelioma.

Treatment is given intravenously over 30-90 minutes with strict monitoring for immune-related adverse events.

Symptoms

Frequent toxicities include skin rash, pruritus, fatigue, headache and low-grade fever.
Severe immune colitis is a hallmark adverse event with watery diarrhea, abdominal cramping and risk of bowel perforation.
Hepatitis with marked transaminase elevation can develop within weeks of treatment.
Endocrine toxicity especially hypophysitis presents with persistent headache, visual disturbance, fatigue and electrolyte abnormalities.
Less common but serious events include pneumonitis, nephritis, neuropathies, uveitis and severe cutaneous reactions.

Risk Factors

History of autoimmune disease or organ transplantation significantly raises the risk of severe toxicity.
Combination with nivolumab increases overall and high-grade immune-related event rates.
Older age, baseline organ dysfunction and chronic infections require careful evaluation.
Concurrent or recent use of strong immunosuppressants may interfere with efficacy.
Genetic predisposition and microbiome differences may influence both response and toxicity.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Persistent diarrhea, blood in stool, severe abdominal pain or fever should be reported urgently.
  • Severe headache, visual changes, vomiting, hypotension or extreme fatigue may indicate hypophysitis.
  • Yellowing of skin, dark urine or marked liver enzyme elevation requires immediate evaluation.
  • New shortness of breath, dry cough or chest discomfort may signal pneumonitis.
  • Skin reactions with blistering, mucosal involvement or neurological deficits warrant emergency assessment.

Treatment Methods

01
Grade 1 events allow continuation of therapy with topical or supportive management and weekly monitoring.
02
Grade 2 events typically require treatment interruption and oral prednisone 0.5-1 mg/kg/day with gradual taper over 4-6 weeks.
03
Grade 3-4 events demand permanent discontinuation of ipilimumab, methylprednisolone 1-2 mg/kg/day and prompt addition of infliximab or vedolizumab for refractory colitis.
04
Hypophysitis is treated with hormone replacement (hydrocortisone, levothyroxine, sex hormones) and high-dose steroids only if symptomatic mass effect.
05
Multidisciplinary care, patient education on early symptom reporting and standardized algorithms are critical to safe delivery and continuation of cancer therapy.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.